Fremanezumab was discovered and developed by Rinat Neuroscience, was acquired by Pfizer in 2006, and was then licensed to Teva.[10] It was approved by the US Food and Drug Administration in September 2018.[11] In March 2019, fremanezumab was approved for marketing and use in the European Union.[3][12]